Eyeworld

OCTOBER 2020 | EYEWORLD | 21 by Shravan Savant, MD, Young Seol, MD, and Harsha Reddy, MD The authors collected data from the Euro- pean Registry of Quality Outcomes for Cata- ract and Refractive Surgery (EUREQUO). This database was created by the European Society of Cataract and Refractive Surgeons as a quality registry of self-reported outcomes for cataract surgery. Preoperative data reported includes year of birth, sex, eye, best-corrected distance visual acuity, target refraction, co-existing eye diseases, surgical difficulties, and previous C ataract extraction is one of the most common surgical procedures in the world. In an attempt to bet- ter risk-stratify patients and predict surgical outcomes, many studies have analyzed the relationships between cataract surgery and other ocular and systemic conditions. In this study, Lundstrom et al. assessed demographic data, preoperative and operative factors, and surgical outcomes of eyes that underwent cataract surgery after vitrectomy. Review of "Cataract surgery of eyes with previous vitrectomy – risks and benefits as reflected in the European Registry of Quality Outcomes for Cataract and Refractive Surgery" continued on page 22 Harsha Reddy, MD Director of Residency Education New York Eye and Ear Infirmary of Mount Sinai New York, New York Shravan Savant, MD PGY-3 Ophthalmology Resident New York Eye and Ear Infirmary of Mount Sinai Young Seol, MD PGY-3 Ophthalmology Resident New York Eye and Ear Infirmary of Mount Sinai without antibiotic resistance and no damage to healthy cells at the dosage used. In terms of market size, Prof. Shah said there are up to 300,000 corneal infections an- nually in the U.S. In the developing world, India for example, there are about 2 million per year causing monocular blindness, he said. There is also a veterinary application that has a market size of 10 times that of the human market. Patents have been submitted for even wider indications for human use, which will expand the indications by a magnitude of order. Prof. Shah said that the costs will vary per market, but it may be possible for the device to be free with just license fees for use. He expects the device to complete human donor cornea studies and gain approval to begin human stud- ies by fall 2022. Veterinary studies will start in spring 2021. He is looking for $2 million in capital to start followed by an additional $8 million. Prof. Shah said he hopes some of this funding will come from humanitarian sources. During discussion with the judges, Dr. Lindstrom asked if this device could ever be self-administered. Prof. Shah said given that distance and light dosage needs to be precise, at this point it needs to be managed by a health- care professional. Mr. Mazzo said Prof. Shah might want to consider pursuing the veterinary angle before human treatments because it is cash pay. Prof. Shah said that he envisions this device to be a standard-of-care instrument/treatment in every eyecare provider's office. And the winner is … • First $25,000: Prof. Shah with Photon Thera- peutics Ltd • Second $15,000: Dr. Nankani with Bynocs • Third $5,000: Dr. Roop with the EDGE-less Diffractive Lens "We look forward to the third Winning Pitch Challenge next year," Dr. Holland said. "The program returns live at the 2021 ASCRS Annual Meeting in San Francisco. We expect more outstanding and innovative ideas to be presented." "If you have an idea, go to Winningpitch- challenge.net, learn about the process, and submit your idea," Dr. Thompson said. "We are here to help you." continued from page 18 EYEWORLD JOURNAL CLUB

• Blank Page
• Blank Page (1)